甲状腺功能减退症 中国就医指南

Hypothyroidism is a common endocrine disorder characterized by insufficient production or action of thyroid hormones—primarily thyroxine (T4) and triiodothyronine (T3)—by the thyroid gland. This hormonal deficiency leads to a generalized slowing of metabolic processes across multiple organ systems. The most frequent cause worldwide is autoimmune thyroiditis, particularly Hashimoto’s thyroiditis, in which cytotoxic T lymphocytes and autoantibodies (e.g., anti-thyroid peroxidase and anti-thyroglobulin antibodies) progressively destroy thyroid follicular cells. Other etiologies include iodine deficiency (endemic in certain regions), postpartum thyroiditis, radiation-induced thyroid damage (e.g., after radioactive iodine therapy or external beam radiotherapy), surgical thyroidectomy, congenital hypothyroidism, and medications such as lithium or amiodarone. Central (secondary or tertiary) hypothyroidism—originating from pituitary or hypothalamic dysfunction—is rare but clinically significant and requires distinct diagnostic evaluation. Epidemiologically, hypothyroidism affects approximately 1–2% of the global population, with prevalence rising sharply with age and showing a strong female predominance (female-to-male ratio ~5–10:1). In China, community-based studies estimate a prevalence of 1.1–2.4% among adults, with higher rates observed in iodine-sufficient urban areas due to increased autoimmune disease detection. Key risk factors include female sex, age over 60 years, personal or family history of autoimmune disorders (e.g., type 1 diabetes, rheumatoid arthritis, vitiligo), prior neck irradiation or thyroid surgery, pregnancy or recent childbirth, and iodine excess or deficiency. Untreated or suboptimally managed hypothyroidism significantly impairs quality of life: patients commonly report persistent fatigue, brain fog, depression, impaired concentration, cold intolerance, weight gain despite reduced appetite, dry skin, hair thinning, constipation, menstrual irregularities, and reduced exercise tolerance. Severe cases may progress to myxedema coma—a life-threatening emergency marked by hypothermia, bradycardia, hypoventilation, and altered mental status. Early diagnosis—via sensitive TSH assay followed by free T4 measurement—and lifelong levothyroxine replacement therapy are highly effective in restoring euthyroidism and reversing symptoms. However, adherence challenges, dosing inaccuracies, and comorbidities (e.g., malabsorption syndromes, heart failure) can complicate management. With appropriate monitoring and individualized treatment, most patients achieve full functional recovery and maintain normal life expectancy.

# 甲状腺功能减退症治疗方案与费用明细（内分泌科）

一、非手术/保守治疗（一线方案）

适用人群：原发性甲减（如桥本甲状腺炎）、术后/放射性碘治疗后甲减、轻中度TSH升高（<20 mU/L）且无心衰/黏液性水肿昏迷者。

• •药物治疗：左甲状腺素钠片（优甲乐®）

- 药品费：30–120元/月（国产仿制药至进口原研）

• •必需检查费（首年）：

- 年度复查（TSH+FT4）：180–260元/次

二、手术/介入方案（极少适用）

注：甲减本身不需手术；仅当合并压迫性巨大结节/可疑恶性结节导致继发性甲减时，按甲状腺癌或结节手术处理。

• •术前评估（超声+细针穿刺+FNA病理+心肺功能）：2,100–3,500元
• •甲状腺全切/近全切术（三甲医院）：28,000–45,000元（含麻醉、住院、病理）

三、特殊复杂情况处理

• •黏液性水肿昏迷（危重症）：ICU监护+静脉左甲状腺素+糖皮质激素+支持治疗：50,000–120,000元/疗程
• •妊娠期甲减：TSH目标更严格，需每月监测，药品+检查总成本约2,400–3,600元/孕程

四、方案快速选择指南

• •预算有限/初诊稳定患者：优选国产左甲状腺素+年度复查 → 年支出约1,200–2,000元
• •妊娠或老年伴心功能不全者：进口优甲乐+双周随访 → 年支出约3,000–4,500元
• •危重症昏迷：立即转内分泌ICU，费用以抢救时效计，不可延迟决策。